Metsera Board Approves Novo Nordisk $10B Enhanced Acquisition Offer

Metsera Inc.'s Board of Directors has declared Novo Nordisk's revised acquisition proposal superior to Pfizer's offer. Novo Nordisk proposes $62.20 cash per share plus contingent value rights up to $24.00 per share, valuing Metsera at approximately $10 billion—a 159% increase over its market value before the Pfizer deal announcement. The acquisition involves a two-step process: an initial cash payment with issuance of non-voting preferred stock, followed by contingent payments based on regulatory and development milestones. Pfizer has two days to adjust its offer in response. Novo Nordisk, a global leader in diabetes care with a strong market position and financial health, aims to expand strategically in the pharmaceutical sector through this acquisition. The enhanced proposal underscores Novo Nordisk's commitment to strengthening its portfolio and market reach.